

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 1)\*

**Allena Pharmaceuticals, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.001 per share**

(Title of Class of Securities)

**018119107**

(CUSIP Number)

**December 31, 2019**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

1. Name of Reporting Persons:  
HBM BioCapital II LP
- 
2. Check the Appropriate Box if a Member of a Group
- (a)
- (b)
- 
3. SEC Use Only
- 
4. Citizenship or Place of Organization:  
Jersey, Channel Islands
- 
5. Sole Voting Power:  
0
- 
6. Shared Voting Power:  
619,073
- 
7. Sole Dispositive Power:  
0
- 
8. Shared Dispositive Power:  
619,073
- 
9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
619,073
- 
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 
11. Percent of Class Represented by Amount in Row (9):  
2.6% (1)
- 
12. Type of Reporting Person (See Instructions):  
PN
- 

---

(1) Based on 23,465,665 shares of Common Stock outstanding, as reported in the Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2019.

1. Name of Reporting Persons:  
HBM BioCapital II Management Ltd.
- 
2. Check the Appropriate Box if a Member of a Group  
(a)   
(b)
- 
3. SEC Use Only
- 
4. Citizenship or Place of Organization:  
Jersey, Channel Islands
- 
- |   |    |                                      |
|---|----|--------------------------------------|
|   | 5. | Sole Voting Power:<br>0              |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | 6. | Shared Voting Power:<br>619,073      |
|   | 7. | Sole Dispositive Power:<br>0         |
|   | 8. | Shared Dispositive Power:<br>619,073 |
- 
9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
619,073
- 
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 
11. Percent of Class Represented by Amount in Row (9):  
2.6% (1)
- 
12. Type of Reporting Person (See Instructions):  
CO, HC
- 

---

(1) Based on 23,465,665 shares of Common Stock outstanding, as reported in the Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2019.

**Item 1.** (a). Name of Issuer  
Allena Pharmaceuticals, Inc.  
\_\_\_\_\_  
(b). Address of Issuer's Principal Executive Offices:  
One Newton Executive Park, Suite 202  
Newton, MA 02462  
\_\_\_\_\_

**Item 2(a).** Name of Person Filing  
See Item 2(c) below.  
\_\_\_\_\_

**Item 2(b).** Address of Principal Business Office  
See Item 2(c) below.  
\_\_\_\_\_

**Item 2(c).** Citizenship  
(i) HBM BioCapital II LP  
11-15 Seaton Place  
St. Helier Y9  
JE4 0QH  
Citizenship: Jersey, Channel Islands  
  
(ii) HBM BioCapital II Management Ltd.  
11-15 Seaton Place  
St. Helier Y9  
JE4 0QH  
Citizenship: Jersey, Channel Islands

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."  
\_\_\_\_\_

**Item 2(d).** Title of Class of Securities:  
Common Stock  
\_\_\_\_\_

**Item 2(e).** CUSIP Number:  
018119107  
\_\_\_\_\_

**Item 3.** **If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:**  
Not Applicable.

**Item 4. Ownership.**

(a) Amount beneficially owned:

619,073 <sup>(1)</sup>

---

(b) Percent of class:

2.6% <sup>(2)</sup>

---

(c) Number of shares as to which the reporting person has:

HBM BioCapital II LP

---

(i) Sole power to vote or to direct the vote:

0

---

(ii) Shared power to vote or to direct the vote:

619,073 <sup>(1)</sup>

---

(iii) Sole power to dispose or to direct the disposition of:

0

---

(iv) Shared power to dispose or to direct the disposition of:

619,073 <sup>(1)</sup>

---

HBM BioCapital II Management Ltd.

---

(i) Sole power to vote or to direct the vote:

0

---

(ii) Shared power to vote or to direct the vote:

619,073 <sup>(1)</sup>

---

(iii) Sole power to dispose or to direct the disposition of:

0

---

(iv) Shared power to dispose or to direct the disposition of:

619,073 <sup>(1)</sup>

---

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not Applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not Applicable.

**Item 9. Notice of Dissolution of Group.**

Not Applicable.

---

(1) The board of directors of HBM BioCapital II Management Ltd., the general partner of HBM BioCapital II LP, has voting and dispositive power with respect to the shares. The board of directors of HBM BioCapital II Management Ltd. consists of Mark Wanless, Andrew Wignall and Jim Millen, none of whom has individual voting or investment power with respect to the shares.

(2) Based on 23,465,665 shares of Common Stock outstanding, as reported in the Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2019.



**Item 10. Certification.**

Not Applicable.

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2020

HBM BIOCAPITAL II LP

By: /s/ Mathew Hague

Name: Mathew Hague

Title: Authorized Signatory

By: /s/ Gunarathnam Gunasekaran

Name: Gunarathnam Gunasekaran

Title: Authorized Signatory

HBM BIOCAPITAL II MANAGEMENT LTD.

By: /s/ Mathew Hague

Name: Mathew Hague

Title: Authorized Signatory

By: /s/ Gunarathnam Gunasekaran

Name: Gunarathnam Gunasekaran

Title: Authorized Signatory

SIGNATURE PAGE TO SCHEDULE 13G AMENDMENT NO.1 (ALLENA PHARMACEUTICALS, INC.)

**EXHIBIT LIST**

Exhibit 1      [Joint Filing Agreement, dated as of February 11, 2020, by and between HBM BioCapital II LP and HBM BioCapital II Management Ltd.](#)



JOINT FILING AGREEMENT

The undersigned hereby agree that this Schedule 13G with respect to the common stock, par value \$0.001 per share, of Allena Pharmaceuticals, Inc., a Delaware corporation, is, and any amendments hereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 11, 2020

HBM BIOCAPITAL II LP

By: /s/ Mathew Hague  
Name: Mathew Hague  
Title: Authorized Signatory

By: /s/ Gunarathnam Gunasekaran  
Name: Gunarathnam Gunasekaran  
Title: Authorized Signatory

HBM BIOCAPITAL II MANAGEMENT LTD.

By: /s/ Matthew Hague  
Name: Mathew Hague  
Title: Authorized Signatory

By: /s/ Gunarathnam Gunasekaran  
Name: Gunarathnam Gunasekaran  
Title: Authorized Signatory

SIGNATURE PAGE TO JOINT FILING AGREEMENT (ALLENA PHARMACEUTICALS, INC.)

---